[go: up one dir, main page]

WO2005074378A2 - Dispositif et methode de reduction de l'apport calorique - Google Patents

Dispositif et methode de reduction de l'apport calorique Download PDF

Info

Publication number
WO2005074378A2
WO2005074378A2 PCT/IL2005/000154 IL2005000154W WO2005074378A2 WO 2005074378 A2 WO2005074378 A2 WO 2005074378A2 IL 2005000154 W IL2005000154 W IL 2005000154W WO 2005074378 A2 WO2005074378 A2 WO 2005074378A2
Authority
WO
WIPO (PCT)
Prior art keywords
capturing
food
agents
food ingredients
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/000154
Other languages
English (en)
Other versions
WO2005074378A3 (fr
Inventor
Itzhak Katz
Amir Alon
Benjamine Alspector
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP05703196A priority Critical patent/EP1718279A2/fr
Publication of WO2005074378A2 publication Critical patent/WO2005074378A2/fr
Publication of WO2005074378A3 publication Critical patent/WO2005074378A3/fr
Anticipated expiration legal-status Critical
Priority to US12/757,841 priority patent/US20100196470A1/en
Priority to US12/757,843 priority patent/US9220688B2/en
Priority to US14/982,871 priority patent/US9724306B2/en
Priority to US15/672,169 priority patent/US11786474B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

  • the present invention relates in general to a device and method for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach and/or anywhere else in the GI tract, into entrapping members; moving the entrapping member containing said food down the GI tract, thus excluding at least part of the food intake from being absorbed in the small intestine and further down the GI tract.
  • Obesity is a chronic disease due to excess fat storage, a genetic predisposition, and strong environmental contributions. This problem is worldwide, and the incidence is increasing daily. There are medical, physical, social, economic, and psychological comorbid conditions associated with obesity. There is no cure for obesity except possibly prevention. Non-surgical treatment has been inadequate in providing sustained weight loss. Currently, surgery offers the only viable treatment option with long-term weight loss and maintenance for the morbidly obese. Surgeries for weight loss are called bariatric surgeries. There is no one operation that is effective for all patients. Gastric bypass operations are the most common operations currently used. Because there are inherent complications from surgeries, bariatric surgeries should be performed in a multidisciplinary setting. The laparoscopic approach is being used by some surgeons in performing the various operations.
  • the success rate usually defined as >50% excess weight loss that is maintained for at least five years from bariatric surgery— ranges from 40% in the simple to >70% in the complex operations.
  • the weight loss from surgical treatment results in significant improvements and, in some cases, complete resolution of comorbid conditions associated with obesity. Patients undergoing surgery for obesity need lifelong nutritional supplements and medical monitoring.
  • Yet another method employs the placement of a band around a portion of the stomach thereby compressing the stomach and creating a stoma opening that is less than the normal interior diameter of the stomach for restricting food intake into the lower digestive portion of the stomach.
  • Kuzmak et al in U.S. Pat have described such a band. No. 4,592,339. It comprises a substantially non-extensible belt-like strap, which constrictively encircles the outside of the stomach thereby preventing the stoma opening from expanding.
  • Kuzmak et al also describe bands, which include a balloon-like section that is expandable and deflatable through a remote injection site. The balloon-like expandable section is used to adjust the size of the stoma opening both intra-operatively and post-operatively
  • the present invention relates on a lipid absorption polymer having an prolonged equilibrium period in the range of 4-8 hours so as to keep the absorption step active during the relevant period in the digestion tract.
  • the invention seeks to provide a successful and non-invasive alternative to existing approaches for controlling obesity.
  • the invention objective is to substantially reduce the caloric efficiency of the digestive tract by capturing food being digested in the stomach and/or anywhere else in the GI tract into entrapping members; moving the entrapping member containing the entrapped food ingredients down the gastrointestinal tract, thus excluding at least part of the entrapped food from being absorbed in the small intestine.
  • Another objective of this invention is to introduce a lipid absorption polymer having an prolonged equilibrium period in the range of 4-8 hours so as to keep the absorption step active during the relevant period in the digestion tract.
  • Another objective of this invention is to interfere with the micelles formation and capture the free lipids contained within
  • Another objective of this invention is to provide a delivery system of the material via means of compressing the material so that it takes less space in the intake, and when the capsule, for example, opens up or dissolves, the individual particles of the material expand to accommodate the captured liquids.
  • the device is comprised of a capsule system for oral delivery.
  • the capsule system is comprised of an external capsule made of gelatin - as an example that dissolves in accordance with a temporal preset, which allows the food intake to be at least partially fluidic.
  • the capsule system is further comprised of an internal permeable bag having a structure such as meshed, woven or fibers, made of disintegrable material such as gelatin for example, which bag contain expandable, super absorbent beads, which dry beads are larger than the pores of the bag, which bag is inflatable.
  • the internal bag further contains a coating capsule, which dissolves at this time and coats the expandable beads, to seals and protects them from disintegration or prevent leakage of entrapped liquid, throughout their journey out of the GI tract.
  • a capsule is a sealed container and a bag is a permeable containers.
  • the external capsule contains folded mechanical structures, which open up to captures some of the stomach content and protects them from disintegration throughout their journey through and out of the GI tract.
  • FIG. 1 is a view of the assembled device.
  • FIG. 2a is a view of the external capsule.
  • FIG. 2b is a view of the internal bag.
  • FIG. 2c is a view of an expandable bead.
  • FIG. 2d is a view of a coating capsule.
  • FIG. 3 illustrates a basic embodiment of this invention depicting an outer capsule containing super absorbent expandable beads.
  • FIG. 4a illustrates of the capsule system entering the stomach at tl.
  • FIG. 4b illustrates the external capsule dissolving at t2.
  • FIG. 4c illustrates the expandable beads expanding as they absorb stomach fluids.
  • FIG. 4d illustrates the expandable beads reaching the size limits of the internal bag at t4.
  • FIG. 4e illustrates the rupture of the coating capsule at t4.
  • FIG. 4f illustrates the internal capsule dissolving at t5.
  • FIG. 4g and FIG. 3h illustrate the draining stage of the coated at t6.
  • FIG. 5 is a temporal illustration of a full cycle of the process.
  • FIGs. 6a-d illustrates another embodiment of the invention.
  • FIGs. 7a-c illustrates another embodiment of the invention.
  • FIGs. 8a-c illustrates yet another embodiment of the invention.
  • FIG. 9 illustrates an embodiment for loading the force into the small structures.
  • cross-linked polymer beads such as Hydrogels, supper absorb
  • the pill is ingested, and the capsule 100 dissolves at a temporal preset, Beads 300 which are now in contact with the content of the food being digested, absorbs caloric enriched liquid and swells.
  • Beads 300 which are now in contact with the content of the food being digested, absorbs caloric enriched liquid and swells.
  • the beads along with content of the stomach are moved into the small intestine, where the entrapped content of the beads are practically not involved in the digestion and absorbing steps in the intestine. It is plausible to design the beads such that they will continue to absorb digested food in the small intestine and further down the GI tract.
  • the beads are pre coated or pre absorbed by a composition capable of forming at least a partial nutrient barrier on small intestine.
  • the composition helps further to reduce the absorption of food in case of leaking from the bead.
  • FIG 1 is a view of the assembled capsule system. It comprises an external capsule 100 which can be made of a biocompatible material such as gelatin, an internal bag 200 which can be made from gelatin with a net like structure, absorbing beads 300 which can be made from Hydrogels and coating capsule(s) 400.
  • an external capsule 100 which can be made of a biocompatible material such as gelatin
  • an internal bag 200 which can be made from gelatin with a net like structure
  • absorbing beads 300 which can be made from Hydrogels and coating capsule(s) 400.
  • FIG 2a illustrates the opened external capsule, which opens at time t2 (see FIG 4). It cans also dissolve with control thickness or any other known technique.
  • FIG 4a illustrates the assembled capsule being swallowed by the patient at time tl (see FIG 5) which is a while after he started his meal at time tO (see FIG 5).
  • FIG. 2b is a view of the internal bag
  • FIG. 2c is a view of an expandable bead
  • FIG. 2d is a view of a coating capsule.
  • FIG 4b illustrates the dissolution of the external capsule in the stomach 10 at time t2. At this time the super absorbing expandable beads are exposed to the stomach fluids and start absorbing them, as illustrated in FIG 4c and continues at time period t3 (see FIG 5).
  • the expandable beads 300 fill out the space allowed by the internal bag 200, as illustrated in FIG 4d, they press against the coating capsule(s) 400.
  • the internal bag dissolves, all the expandable beads are free to move about the GI tract, at time period t6 (see FIG 5), and they are drained untouched through and out of the GI tract, as illustrated in FIGs 4g and 4h.
  • the expandable beads 300 dissolve after a preset number of days, in case they were not able to clear out of the GI tract. In another option, the patient drinks a liquid that dissolves expandable beads 300.
  • time t5 when the internal bag 200 dissolves and the expandable beads 300 are free to move about the GI tract, occurs only after the fed mode of the stomach is finished, and the stomach goes into its maintenance mode.
  • the fluids pass on their way to the super absorbable beads through a filter which is wide on the outer side and narrow in the inner side. This makes it easy for the fluids the flow inward the beads and hard to flow back.
  • a polymer capable of absorbing lipid having an prolonged equilibrium period in the range of 4-8 hours so as to keep the absorption step active during the relevant period in the digestion tract is provided.
  • One such polymer for example is Polypore, having high absorption ratio of 13gr lipid to lgr polymer
  • Another embodiment of the present invention is to interfere with the micelles which are necessary for the lipid digestion activity.
  • the purpose of the polymer is to disassemble the micelles and extract the lipids.
  • a polymer is, for example, isss Gantrez® series, especially Gantrez 225 and Gantrez 425.
  • FIGs 6a-6d Another embodiment of this invention is illustrated in FIGs 6a-6d.
  • the inner bag is in the form of a folded basket 202 which contains a stack of spheres 500 each of which is split into to halves 501 and 502 which are comiected by a spring like comiection 503 that the force embedded in it will close up the spheres to the poison 504 in a relaxed mode.
  • the external capsule 100 dissolves, the force embedded in the stacked up halve spheres 500 will cause the optional basket 202 to open up optionally locked into the position illustrated in FIG 6d. This allows the half spheres to close up to position 504 which scoops up the food being digested while closing up.
  • the sphere 504 is now small enough to leave the basket 202 through the opening 203, being pushed by the next pair of half spheres.
  • the last pair of half spheres in the stack may remain in the basket 202, which dissolves after a preset time and clears out down the GI tract.
  • the optional basket 202 is designed to avoid the possibility that the closing sphere will harm the stomach inner walls.
  • the spheres 500 are of a size appropriate to be able to travel through the GI tract.
  • the closed spheres are made of a substantially ingestible biocompatible material and remain closed and untouched through the journey down and out of the GI tract.
  • the spheres 500 dissolve after a preset number of days, in case they were not able to clear out of the GI tract.
  • the patient drinks a liquid that dissolves spheres 500.
  • FIGs 7a-7c Another embodiment of this invention is illustrated in FIGs 7a-7c.
  • the capsule is filled up with number of folded stent like structures 600.
  • a force will cause the stents 600 to open up and lock into the position illustrated in FIG 7c.
  • the force can be embedded in the structures 600, apply via external or internal spring (not shown) or generated internally or externally via chemical reaction with the stomach content.
  • stents 600 open up inside the stomach they will suck up some of the content into the stents.
  • the stents 600 are built such that they have entry holes 604 through which the content is sucked up.
  • entry holes 604 are equipped with a directional valve such that the stomach content can only enter into the stents but can not escape.
  • the size of the opened stents 600 is designed to be able to travel through the GI tract.
  • the stents are made of a substantially ingestible material and remain closed and untouched throughout their journey down and out of the GI tract.
  • the folded structures can also be polymer beads and the force applied to them before delivery to compress the beads substantially so that they open inside the GI tract to capture various liquids.
  • One such polymer for example, is Polypore, having high absorption ratio of 13gr lipid to lgr polymer and high ratio of its free form volume to its compressed form volume.
  • the force (such as spring force or elastic force) is being loaded into the small structures 700 before using the capsule.
  • An example of such embodiment is shown in Fig 9.
  • Turning the handle 802 in direction 806 moves the bar 804 in direction 808.
  • the capsule half 101 is pushed towards the second half 102 and the small structures 700 are compressed. This will overcome the possibility that the force will deteriorate over time.
  • Figure 9 shows a device for compressing the small structures and encapsulating them to form the pill to be swallowed.
  • FIGs 8a-8c Another embodiment of this invention is illustrated in FIGs 8a-8c.
  • the capsule is filled up with a number of folded structures 700.
  • the force embedded within the structures will cause the structures 700 to open up into the position illustrated in FIG 8c.
  • the force can be embedded in the structures 700, in the manufacturing process by taking a semi rigid structure and forcing it into a collapsed form by applying pressure.
  • the kinetic energy stored in the structures 700 will be used to restore the structures into their natural form once the capsule 101 has opened up. This force is designed so that it can over come the pressure inside the stomach. While structures 700 open up inside the stomach they will suck up some of the content into the structures 700.
  • the structures 700 are made up such that they have entry holes 703 through which the content is sucked up.
  • entry holes 703 are equipped with a directional valve such that the stomach content can only enter into the structures 700 but cannot escape.
  • the size of the opened stents 700 is designed to be able to travel through the GI tract.
  • the full structures 700 are made of a substantially ingestible material and remain closed and untouched throughout the journey down and out of the GI tract.
  • the folded structures are polymer beads and the force applied to them before delivery to compress the beads substantially so that they take less space on the intake but open inside the GI tract to capture various liquids.
  • One such polymer for example, is Polypore, having high absorption ratio of 13gr lipid to lgr polymer and high ratio of its free form volume to its compressed form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Formation And Processing Of Food Products (AREA)

Abstract

L'invention concerne des dispositifs et des méthodes qui permettent de réduire sensiblement l'efficience calorique du système gastro-intestinal par la capture des aliments en cours de digestion dans l'estomac et/ou dans n'importe quelle autre partie du système gastro-intestinal; par l'absorption ou l'encapsulation des aliments capturés en plusieurs éléments de capture; et par l'acheminement desdits éléments de capture contenant les aliments encapsulés ingestibles dans le système gastro-intestinal, pratiquement hors de portée des organes d'absorption du système gastro-intestinal, ce qui exclut les ingrédients piégés du processus de digestion et/ou d'absorption. Le dispositif est conçu pour s'administrer par voie orale. Le système peut être constitué d'un liquide, d'un aliment en barres ou d'un système de capsule. Le système de capsule est constitué d'une capsule extérieure qui se dissout en fonction d'un critère préétabli temporel ou tributaire du pH, qui rend l'ingestion alimentaire au moins partiellement fluide. Le système de capsule est constitué en outre d'un mécanisme conçu pour capturer et isoler une partie des aliments en cours de digestion.
PCT/IL2005/000154 2004-02-10 2005-02-08 Dispositif et methode de reduction de l'apport calorique Ceased WO2005074378A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05703196A EP1718279A2 (fr) 2004-02-10 2005-02-08 Dispositif et methode de reduction de l'apport calorique
US12/757,841 US20100196470A1 (en) 2004-02-10 2010-04-09 Device and method for reducing calorie intake
US12/757,843 US9220688B2 (en) 2004-02-10 2010-04-09 Device and method for reducing calorie intake
US14/982,871 US9724306B2 (en) 2004-02-10 2015-12-29 Device and method for reducing calorie intake
US15/672,169 US11786474B2 (en) 2004-02-10 2017-08-08 Device and method for reducing calorie intake

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54284304P 2004-02-10 2004-02-10
US60/542,843 2004-02-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/581,175 Continuation US20080089933A1 (en) 2004-02-10 2006-10-16 Device and method for reducing calorie intake

Publications (2)

Publication Number Publication Date
WO2005074378A2 true WO2005074378A2 (fr) 2005-08-18
WO2005074378A3 WO2005074378A3 (fr) 2005-10-13

Family

ID=34837567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000154 Ceased WO2005074378A2 (fr) 2004-02-10 2005-02-08 Dispositif et methode de reduction de l'apport calorique

Country Status (2)

Country Link
EP (1) EP1718279A2 (fr)
WO (1) WO2005074378A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122499A3 (fr) * 2009-04-20 2011-05-19 Ecole Polytechnique Federale De Lausanne (Epfl) Récipients assemblés dans un fluide et production correspondante
WO2011149877A3 (fr) * 2010-05-26 2012-08-30 Ethicon Endo-Surgery, Inc. Procédés et dispositifs d'élution intraluminale de substance thérapeutique induisant un frein intestinal
US20120251589A1 (en) * 2011-03-29 2012-10-04 Paolo Costa Devices and methods for weight control and weight loss
JP2015515308A (ja) * 2012-03-27 2015-05-28 テラテクネ インコーポレイティッド 高多孔性セルローススポンジ
US9220688B2 (en) 2004-02-10 2015-12-29 Slendine Sa Device and method for reducing calorie intake
CN111494332A (zh) * 2012-03-27 2020-08-07 斯伦迪内股份公司 高孔隙度纤维素海绵

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220688B2 (en) 2004-02-10 2015-12-29 Slendine Sa Device and method for reducing calorie intake
US9724306B2 (en) 2004-02-10 2017-08-08 Slendine Ag Device and method for reducing calorie intake
US11786474B2 (en) 2004-02-10 2023-10-17 Biolumen Inc. Device and method for reducing calorie intake
WO2010122499A3 (fr) * 2009-04-20 2011-05-19 Ecole Polytechnique Federale De Lausanne (Epfl) Récipients assemblés dans un fluide et production correspondante
WO2011149877A3 (fr) * 2010-05-26 2012-08-30 Ethicon Endo-Surgery, Inc. Procédés et dispositifs d'élution intraluminale de substance thérapeutique induisant un frein intestinal
US8876761B2 (en) 2010-05-26 2014-11-04 Ethicon Endo-Surgery, Inc. Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
US20120251589A1 (en) * 2011-03-29 2012-10-04 Paolo Costa Devices and methods for weight control and weight loss
US8722066B2 (en) * 2011-03-29 2014-05-13 Primigenia, LLC Devices and methods for weight control and weight loss
US9320715B2 (en) 2011-03-29 2016-04-26 Slendine Sa Devices and methods for weight control and weight loss
JP2015515308A (ja) * 2012-03-27 2015-05-28 テラテクネ インコーポレイティッド 高多孔性セルローススポンジ
CN111494332A (zh) * 2012-03-27 2020-08-07 斯伦迪内股份公司 高孔隙度纤维素海绵

Also Published As

Publication number Publication date
EP1718279A2 (fr) 2006-11-08
WO2005074378A3 (fr) 2005-10-13

Similar Documents

Publication Publication Date Title
US11786474B2 (en) Device and method for reducing calorie intake
JP5220001B2 (ja) 生体内分解性の自己展開式の胃内インプラントおよび胃以外のインプラント
CN104168945B (zh) 用于在身体内配置和释放暂时植入物的设备
EP2004106B1 (fr) Accessoire ingerable pour le contrôle du poids
US7674396B2 (en) Method and system for treatment of eating disorders
US20090259246A1 (en) Intragastric Volume-Occupying Device
US20180200094A1 (en) Passive Caloric Bypass Device
CN107530538B (zh) 用于在身体内部署并释放临时植入物的方法和装置
US20110082419A1 (en) Bezoar-forming units for weight control
WO2020048029A1 (fr) Implant naturellement dégradable
Martin et al. Safety of the Ullorex® oral intragastric balloon for the treatment of obesity
EP1718279A2 (fr) Dispositif et methode de reduction de l'apport calorique
US9579227B2 (en) Ingestible implement for weight control
EP2066303B1 (fr) Système de traitement de troubles de l'alimentation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005703196

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005703196

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005703196

Country of ref document: EP